Computational models for clinical applications in personalized medicine—guidelines and recommendations for data integration and model validation

CB Collin, T Gebhardt, M Golebiewski… - Journal of personalized …, 2022 - mdpi.com
The future development of personalized medicine depends on a vast exchange of data from
different sources, as well as harmonized integrative analysis of large-scale clinical health …

Renin–angiotensin–aldosterone pathway modulators in chronic kidney disease: A comparative review

S Alshahrani - Frontiers in Pharmacology, 2023 - frontiersin.org
Chronic kidney disease presents a health challenge that has a complex underlying
pathophysiology, both acquired and inherited. The pharmacotherapeutic treatment options …

Physiologically based pharmacokinetic model to predict metoprolol disposition in healthy and disease populations

A Zamir, MF Rasool, I Imran, H Saeed, S Khalid… - ACS …, 2023 - ACS Publications
The evolution in the development of drugs has increased the popularity of physiologically
based pharmacokinetic (PBPK) models. This study seeks to assess the PK of metoprolol in …

In-depth analysis of physiologically based pharmacokinetic (PBPK) modeling utilization in different application fields using text mining tools

A Krstevska, J Đuriš, S Ibrić, S Cvijić - Pharmaceutics, 2022 - mdpi.com
In the past decade, only a small number of papers have elaborated on the application of
physiologically based pharmacokinetic (PBPK) modeling across different areas. In this …

Application of physiologically based pharmacokinetic modeling to evaluate the drug–drug and drug–disease interactions of apatinib

H Liu, Y Yu, N Guo, X Wang, B Han… - Frontiers in …, 2021 - frontiersin.org
Aim: Apatinib is an orally administered vascular epidermal growth factor receptor (VEGFR)-
tyrosine kinase inhibitors approved for the treatment of advanced gastric adenocarcinoma or …

[HTML][HTML] A physiologically based pharmacokinetic model of cefepime to predict its pharmacokinetics in healthy, pediatric and disease populations

MT Zahid, A Zamir, A Majeed, I Imran, S Alsanea… - Saudi Pharmaceutical …, 2023 - Elsevier
The physiologically based pharmacokinetic modeling (PBPK) approach can predict drug
pharmacokinetics (PK) by combining changes in blood flow and pathophysiological …

Key factors in effective patient-tailored dosing of fluoroquinolones in urological infections: Interindividual pharmacokinetic and pharmacodynamic variability

O Estradé, V Vozmediano, N Carral, A Isla, M González… - Antibiotics, 2022 - mdpi.com
Fluoroquinolones (FQs) are a critical group of antimicrobials prescribed in urological
infections as they have a broad antimicrobial spectrum of activity and a favorable tissue …

Assessment of aging-related function variations of P-gp transporter in old-elderly Chinese CHF patients based on modeling and simulation

C Cui, Y Qu, JEV Sia, Z Zhu, Y Wang, J Ling, H Li… - Clinical …, 2022 - Springer
Background and Objectives P-glycoprotein (P-gp) is one of the most intensely studied
transporters owing to its broad tissue distribution and substrate specificity. Existing research …

Predicting transporter mediated drug–drug interactions via static and dynamic physiologically based pharmacokinetic modeling: A comprehensive insight on where …

G Vijaywargi, S Kollipara, T Ahmed… - … & Drug Disposition, 2023 - Wiley Online Library
The greater utilization and acceptance of physiologically‐based pharmacokinetic (PBPK)
modeling to evaluate the potential metabolic drug–drug interactions is evident by the …

[HTML][HTML] Predicting Food–Drug Interactions between Piperine and CYP3A4 Substrate Drugs Using PBPK Modeling

F Lin, Y Hu, Y Zhang, L Zhao, D Zhong… - International Journal of …, 2024 - mdpi.com
Piperine has been reported to inhibit the enzyme activity of cytochrome P450 (CYP) 3A4.
The aim of this study was to develop and validate a physiologically based pharmacokinetic …